Instil Bio, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Instil Bio, Inc. (NASDAQ: TIL) resulting from allegations that Instil Bio may have issued materially misleading business information to the investing public.

If you purchased Instil Bio securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Instil Bio securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On October 31, 2022, before market hours, Instil Bio issued a press release entitled “Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing” which announced the pause and that the pause was due to “a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured.” Further, the Company announced that “[a]lthough no manufacturing failures have been observed to date in the ongoing Phase 1 trial of ITIL-306, the Company has also voluntarily paused enrollment in this trial as part of its overall manufacturing analysis.” The Company also announced that it “intends to provide an update on the manufacturing analysis by early Q1 2023.”

On this news, Instil Bio’s stock fell $1.95 per share, or 37%, to close at $3.30 per on October 31, 2022.

公司名称: Instil Bio, Inc.
股票代号: TIL
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。